University of California

Meritage Pharma, Inc.

Horizon Orphan LLC

Ranjan Dohil

Jerry Schneider

Seema S Aceves

John Bastian

Malcolm Hill

Elaine Phillips

Quan Nhu

Carlo Ballatore

Ramesh Muttavarapu

Patrice P Rioux

Kathlene Powell

Susan A Phillips

John F Bastian

Seema Aceves

The disclosure provides for new substituted cysteamine and cystamine compounds, pharmaceutical compositions made thereof, and methods thereof including the treatment of any disease or disorder in a subject that can benefit from one or more of the bioprotective effects of the compounds, including but not limited to, binding of cystine, reducing oxidative stress, increasing adiponectin levels and/or increasing brain-derived neurotrophic factors. Examples of such disease and disorders, include but are not limited to, cystinosis, and fatty liver diseases.

Substituted amino-thiol and amino-disulfide compounds, and uses thereof

The disclosure relates to methods and compositions to treat an eosinophilic disease or disorder. More particularly, the disclosure provides methods and compositions for treating eosinophilic esophagitis.

Compositions and methods for treating eosinophilic disorders

The disclosure provides cysteamine salt and cystamine formulations comprising enteric coatings. The disclosure also provides composition for use in treating diseases and disorders that can be treated with cysteamine.

Formulations of cysteamine and cystamine

Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Enterically coated cysteamine, cystamine and derivatives thereof

Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.

Delayed release cysteamine bead formulation, and methods of making and using same

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine or cystamine compositions. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Growing community of inventors

San Diego, CA, United States of America

Ranjan Dohil